Thalamic Volume Loss Reduced in Relapsing, Progressive Multiple Sclerosis Treated With Ocrelizumab - Neurology Live

Ocrelizumab (Ocrevus; Genentech), an anti-CD20 treatment FDA-approved for progressive MS, was shown to reduce thalamic volume loss, with even greater outcomes when initiated earlier.

Using the phase 3 OPERA I and II (NCT01247324; NCT01412333) and ORATORIO (NCT01194570) studies, investigators found significantly reduced thalamic volume loss in patients with relapsing (RMS) and pri… [+4099 chars]

full article...